ClinicalTrials.gg
CompletedNCT03217591Updated Sep 15, 2022Results posted

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

A Phase 2 interventional study of IW-1973 and IW-1973 in Type 2 Diabetes Mellitus With Diabetic Nephropathy, sponsored by Akebia Therapeutics. Completed at 54 sites in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-15.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,121st of 2,957
156 · median 90
Started
2017
with 145 others
Phase 2
391 of 3,304
24 open now
Registered
1,974th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,121st largest by enrollment of the 2,957 interventional ones that give a count, is one of 146 that started in 2017, is one of 391 in phase 2, and was the 1,974th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.

03

Conditions studied

  • Type 2 Diabetes Mellitus With Diabetic Nephropathy
04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patient is an ambulatory male or female from 25 to 75 years old at the Screening Visit.
  • Patient has type 2 diabetes diagnosed by a physician or nurse practitioner ≥6 months before the Screening Visit, has been on ≥1 antihyperglycemic medication for ≥12 weeks preceding the Randomization Visit, and has been on a stable regimen (ie, same drug and same dose) of ≥1 antihyperglycemic medication for ≥28 days preceding the Randomization Visit. (Modification of short-acting insulin throughout the Screening Period will not affect eligibility.)
  • Patient has been on a stable regimen (ie, same drug and dose) of antihypertensive medications, which must include an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), for ≥28 days preceding the Randomization Visit and is expected to remain on their regimen through the Follow-up Visit.
  • Patient has the following:

    1. Estimated (eGFR) 30 to 75 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (1) at the Screening and Baseline Visits
    2. Urine albumin-to-creatinine ratio (UACR) >200 mg/g at the Screening and Baseline Visits and \<5000 mg/g at Screening and Baseline Visits
    3. Serum albumin >3.0 g/dL at the Screening and Baseline Visits
    4. (HbA1c) ≤11% at the Screening and Baseline Visits
    5. Systolic blood pressure (BP) of 110 to 160 mm Hg at the Screening and Baseline Visits
  • Women of must have a negative pregnancy test prior to randomization and must agree to use protocol-specified from the Screening Visit through 60 days after the final dose of study drug.
  • Male patients must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception from the Screening Visit through 60 days after the final dose of study drug.
  • Other inclusion criteria per protocol.

Key Exclusion Criteria:

  • Patient has a history of secondary hypertension (ie, renal artery stenosis, primary aldosteronism, or pheochromocytoma).
  • Patient has a (BMI) \<20 or >45 kg/m2 at the Screening Visit.
  • Patient has a history of dysfunction, hemophilia, von Willebrand disease, coagulation disorder, other bleeding diathesis, or significant, nontraumatic bleeding episode(s), such as from a gastrointestinal source.
  • Patient has hepatic impairment defined as A, B, C.
  • Patient has significant comorbidities (eg, , advanced liver disease, pulmonary hypertension, pulmonary fibrosis, lung disease requiring supplemental oxygen) or other significant conditions that, in the Investigator's opinion, would limit the patient's ability to complete or participate in this clinical study; has been hospitalized for cardiovascular, renal, or metabolic cause in the 3 months before the Screening Visit; or has a of less than 1 year.
  • Patient has had prior dialysis, renal transplant, or planned renal transplant.
  • Patient has clinically active, symptomatic, or unstable coronary artery or heart disease within the 3 months before the Screening Visit, defined as 1 of the following:

    1. Hospitalization for myocardial infarction (MI), unstable angina, or heart failure
    2. New-onset angina with positive functional study or coronary angiogram revealing stenosis
    3. Coronary revascularization procedure
  • Patient has a history of or allergies to any of the inactive ingredients contained in the active or placebo drug products.
  • Patient has previously received IW-1973 in a study, or received an drug during the 30 days or 5 half-lives of that investigational drug (whichever is longer) before the Screening Visit, or is planning to receive another investigational drug at any time during the study.
  • Patient is taking specific inhibitors of phosphodiesterase 5 (PDE5), nonspecific inhibitors of PDE5 (including dipyridamole and theophylline), any supplements for the treatment of erectile dysfunction, riociguat, or nitrates or nitric oxide (NO) donors in any form. These medications and supplements are prohibited from 7 days before Randomization through the duration of the study.
  • Patient is taking strong cytochrome P450 3A () inhibitors (eg, ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, telithromycin, itraconazole, and nefazodone). These medications are prohibited 14 days before Randomization through the duration of the trial.
  • Other exclusion criteria per protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    IW-1973 Low Dose

    Administered daily for 12 weeks

    Drug: IW-1973

  • Experimental
    IW-1973 High Dose

    Administered daily for 12 weeks

    Drug: IW-1973

  • Placebo comparator
    Placebo

    Placebo to match experimental drug administered daily for 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. Causality relationship to study drug was per Investigator assessment.

    Time frame: Day 1 up to Day 115

  2. Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12

    Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as urine albumin (mg per deciliter \[mg/dL\]) / urine creatinine (g/dL). Change from Baseline was calculated as the average of the UCAR values at Weeks 8 and 12 minus the Baseline value. Data were analyzed using a mixed-effects model repeated measures (MMRM) analysis with change from Baseline in log-transformed UACR as the response variable, treatment, visit, treatment-by visit interaction, and Baseline estimated glomerular filtration rate stratum as fixed effects, Baseline log-transformed UACR and Baseline mean arterial pressure as covariates, and unstructured as the variance-covariance structure.

    Time frame: Baseline; Week 8 to Week 12

07

Results

Posted Sep 15, 2022

Participant flow

This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of praliciguat (IW-1973) in participants with type 2 diabetes mellitus with albuminuria who were on a stable regimen of renin-angiotensin system inhibitors.

Participant flow — Overall Study
MilestonePlaceboPraliciguat 20 mgPraliciguat 40 mg
Started545052
Completed514742
Not completed3310
Withdrew: Adverse event126
Withdrew: Withdrawal by subject013
Withdrew: Lost to follow-up100
Withdrew: Protocol violation101

Outcome measures

PrimaryNumber of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. Causality relationship to study drug was per Investigator assessment.

Time frame:
Day 1 up to Day 115
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs
ParticipantsPlaceboPraliciguat 20 mgPraliciguat 40 mg
Any TEAE242122
Study drug-related TEAEs6310
PrimaryPercent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12

Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as urine albumin (mg per deciliter \[mg/dL\]) / urine creatinine (g/dL). Change from Baseline was calculated as the average of the UCAR values at Weeks 8 and 12 minus the Baseline value. Data were analyzed using a mixed-effects model repeated measures (MMRM) analysis with change from Baseline in log-transformed UACR as the response variable, treatment, visit, treatment-by visit interaction, and Baseline estimated glomerular filtration rate stratum as fixed effects, Baseline log-transformed UACR and Baseline mean arterial pressure as covariates, and unstructured as the variance-covariance structure.

Time frame:
Baseline; Week 8 to Week 12
Reported as:
Geometric least squares mean · Percent Change
Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12
Percent ChangePlaceboPraliciguat 20 mgPraliciguat 40 mgPraliciguat Overall
Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12-14.8 (-27.7 to 0.4)-28.4 (-39.4 to -15.3)-27.3 (-39.2 to -13.1)-27.8 (-36.3 to -18.3)
Statistical analysis
  • Placebo vs Praliciguat 20 mg · Mixed Models Analysis · p = =0.2142 · Geometric mean change (%): -16.0 · 90% CI -33.3 to 5.8
  • Placebo vs Praliciguat 40 mg · Mixed Models Analysis · p = =0.2718 · Geometric mean change (%): -14.6 · 90% CI -32.7 to 8.3
  • Placebo vs Praliciguat Overall · Mixed Models Analysis · p = =0.1736 · Geometric mean change (%): -15.3 · 90% CI -30.7 to 3.6

Adverse events

Collected over From first dose of study drug (Day 1) up to Follow-up Visit (Day 115). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/54 (0%)1/54 (1.9%)24/54 (44.4%)
Praliciguat 20 mg0/50 (0%)1/50 (2%)21/50 (42%)
Praliciguat 40 mg0/52 (0%)4/52 (7.7%)21/52 (40.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboPraliciguat 20 mgPraliciguat 40 mg
SyncopeNervous system disorders0/540/502/52
Cerebrovascular accidentNervous system disorders0/541/500/52
Chest painGeneral disorders0/540/501/52
Non-cardiac chest painGeneral disorders0/540/501/52
Road traffic accidentInjury, poisoning and procedural complications0/540/501/52
HypoglycaemiaMetabolism and nutrition disorders0/540/501/52
BronchitisRespiratory, thoracic and mediastinal disorders1/540/500/52
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/540/500/52
PneumoniaRespiratory, thoracic and mediastinal disorders1/540/500/52
Most frequent other events
Showing 10 of 92
Most frequent other events
EventPlaceboPraliciguat 20 mgPraliciguat 40 mg
DizzinessNervous system disorders0/541/504/52
DiarrhoeaGastrointestinal disorders3/543/501/52
Urinary tract infectionInfections and infestations3/541/501/52
ConstipationGastrointestinal disorders1/542/502/52
NauseaGastrointestinal disorders1/541/502/52
Oedema peripheralGeneral disorders0/541/502/52
PyrexiaGeneral disorders0/541/502/52
FatigueGeneral disorders0/540/502/52
Upper respiratory tract infectionInfections and infestations2/540/500/52
LacerationInjury, poisoning and procedural complications2/540/500/52

Baseline characteristics

Intent-to-Treat Population consisted of all randomized participants who received at least 1 dose of study drug.

Age, Customized
Age, Customized(Participants)PlaceboPraliciguat 20 mgPraliciguat 40 mgTotal
18 - 450123
>45 - 6526252374
>6528242779
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPraliciguat 20 mgPraliciguat 40 mgTotal
Female17162053
Male373432103
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPraliciguat 20 mgPraliciguat 40 mgTotal
Hispanic or Latino25303085
Not Hispanic or Latino29202271
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboPraliciguat 20 mgPraliciguat 40 mgTotal
American Indian or Alaska Native0101
Asian3115
Native Hawaiian or Other Pacific Islander0202
Black or African American10131437
White413337111
More than one race0000
Unknown or Not Reported0000
08

Study locations

54 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • California Institute of Renal Research
    Chula Vista, California 91910, United States
  • St. Joseph Heritage Healthcare (St. Jude Hospital DBA)
    Fullerton, California 92835, United States
  • California Institute of Renal Research
    La Mesa, California 91942, United States
  • Torrance Clinical Research Institute, Inc.
    Lomita, California 90717, United States
  • American Institute of Research
    Los Angeles, California 90017, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • California Medical Research Associates, Inc. (CMRA)
    Northridge, California 91324, United States
  • Riverside Nephrology Physicians, Inc.
    Riverside, California 92503, United States
  • California Kidney Specialists
    San Dimas, California 91773, United States
  • North American Research Institute
    San Dimas, California 91773, United States
  • UCLA
    Santa Monica, California 90025, United States
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Creekside Endocrine Associates
    Denver, Colorado 80209, United States
  • Christiana Care Health Services
    Newark, Delaware 19713, United States
  • The George Washington University Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • AGA Clinical Trials
    Hialeah, Florida 33012, United States
  • Sweet Hope Research Speciality, Inc.
    Miami Lakes, Florida 33016, United States
  • Leon Medical Research Corp.
    Miami, Florida 33015, United States
  • Elite Clinical Research
    Miami, Florida 33144, United States
  • DL Research Solutions
    Miami, Florida 33155, United States
  • Premier Research Associates, Inc.
    Miami, Florida 33165, United States
  • IMIC, Inc.
    Palmetto Bay, Florida 33157, United States
  • Atlanta Center for Clinical Research Nephrology
    Atlanta, Georgia 30342, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Gwinnett Biomedical Research
    Lawrenceville, Georgia 30046, United States
  • East Coast Institute for Clinical Research
    Macon, Georgia 31210, United States
  • East Coast Institute for Research
    Macon, Georgia 31210, United States
  • Saltzer Medical Group
    Nampa, Idaho 83686, United States
  • Research by Design, LLC
    Chicago, Illinois 60643, United States
  • American Health Network of Indiana
    Franklin, Indiana 46131, United States
  • My Kidney Center
    Manhattan, Kansas 66502, United States
  • Kentucky Diabetes Endocrinology Center
    Lexington, Kentucky 40503, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Aa Mrc, Llc
    Flint, Michigan 48504, United States
  • St. Louis Heart & Vascular, P.C.
    Saint Louis, Missouri 63136, United States
  • NJ Heart, P.A.
    Linden, New Jersey 07036, United States
  • Albany Medical College, Division of Community Endocrinology
    Albany, New York 12206, United States
  • Physicians East Endocrinology
    Greenville, North Carolina 27834, United States
  • Mountain View Clinical Research
    Greer, South Carolina 29651, United States
  • South Carolina Nephrology & Hypertension Center
    Orangeburg, South Carolina 29118, United States
  • University of Tennessee Health Science Center at Memphis University Hospital
    Memphis, Tennessee 38104, United States
  • Pioneer Research Solutions
    Beaumont, Texas 77702, United States
  • Academy of Diabetes, Thyroid and Endocrine, P.A.
    El Paso, Texas 79935, United States
  • The Medical Group of Texas
    Fort Worth, Texas 76116, United States
  • Rockwood Medical Center
    Fort Worth, Texas 76164, United States
  • Endocrine IPS, PLLC
    Houston, Texas 77079, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77099, United States
  • FMC Science, LLC
    Lampasas, Texas 76550, United States
  • Clinical Advancement Center PLLC
    San Antonio, Texas 78215, United States
  • Briggs Clinical Research
    San Antonio, Texas 78224, United States
  • Burke Internal Medicine and Research
    Burke, Virginia 22015, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Northside Endocrinology
    Spokane, Washington 99208, United States
09

References and documents

Publications

  • Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):59-69. doi: 10.2215/CJN.08410520. Epub 2020 Dec 16. PubMed 33328269 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Aug 2019, 24 months.

Results were first posted in Sep 2022, 3 years after primary completion. A results delay was requested in Aug 2020.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 24 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2017
First posted
Jul 14, 2017
StartActual
Aug 1, 2017
Primary completionActual
Aug 20, 2019
CompletionActual
Aug 20, 2019
Results delay requested
Aug 18, 2020
Results first posted
Sep 15, 2022
Last update
Sep 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03217591
Responsible party
Sponsor
First posted
Jul 14, 2017
Start date
Aug 1, 2017
Primary completion
Aug 20, 2019
Completion
Aug 20, 2019
Results posted
Sep 15, 2022
Last update
Sep 15, 2022

Study contacts

John Hanrahan, MD MPH
study director · Cyclerion Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Praliciguat

Start the discussion